小剂量利培酮联合曲唑酮应用于海洛因成瘾脱毒期的疗效分析

doi:10.12092/j.issn.1009-2501.2019.01.016

摘要/Abstract

摘要：

目的: 探讨小剂量利培酮联合曲唑酮治疗海洛因成瘾脱毒期焦虑、抑郁情绪及失眠的临床疗效及安全性。方法: 将150例海洛因成瘾者随机分成3组，利培酮联合曲唑酮组50例(R+T组)，予小剂量利培酮联合曲唑酮治疗,利培酮日剂量为1～2 mg，bid，早晚服用，曲唑酮日剂量50～200 mg，bid，早晚服用；利培酮组50例（R组），单纯予利培酮治疗，日剂量1～2 mg，bid，早晚服用；曲唑酮组50例（T组），单纯予曲唑酮治疗，日剂量50～200 mg，bid，早晚服用。疗程均为6周。于治疗前及治疗2、4、6周末，采用汉密尔顿焦虑评定量表（HAMA）、汉密尔顿抑郁评定量表（HAMD）及匹茨堡睡眠质量指数量表(PSQI)进行疗效评定，用不良反应量表（TESS）和实验室检查评定安全性。结果: 3组治疗6周末共脱落21例，余下129例完成6周治疗。R+T组在2、4、6周末HAMA、HAMD和PSQI量表评分与治疗前比较均明显下降，差异均有统计学意义（P<0.05）；R组4、6周末HAMA、HAMD和PSQI量表评分与治疗前比较均明显下降，差异均有统计学意义（P<0.05）；T组4、6周末HAMA、HAMD评分与治疗前比较均明显下降，差异均有统计学意义（P<0.05），PSQI量表只在6周末评分有明显下降，差异有统计学意义（P<0.05）。R+T组与R、T组在2、4、6周末HAMA、HAMD和PSQI量表评分比较差异均有统计学意义（P<0.05）。3组TESS评分比较，治疗4、6周末，R+T组与T、R组间TESS评分比较差异均无统计学意义（P>0.05）。结论: 小剂量利培酮联合曲唑酮能够显著改善海洛因成瘾者脱毒期的焦虑，抑郁情绪和睡眠质量，疗效优于单一用药。

关键词: 海洛因成瘾, 利培酮, 曲唑酮, 焦虑, 抑郁, 失眠

Abstract:

AIM: To investigate the clinical efficacy and safety of low dose risperidone combined with trazodone in the treatment of anxiety disorders, depression disorders and insomnia from heroin addicts after detoxification. METHODS: One hundred and fifty patients were divided into 3 groups randomly. Fifty patients of risperidone combined with trazodone group(R+T group) were given low dose risperidone and trazodone.Fifty patients of the trazodone group(T group)were only given trazodone and 50 patients of the risperidone group(R group) were only given low dose risperidone, respectively. Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD) and Pittsburgh Sleep Quality Index (PSQI) were used to evaluate the efficacy before treatment and at the end of 2, 4, 6 weeks after treatment. The safety was evaluated with Treatment Emergent Side-effect Scale (TESS) and laboratory test. RESULTS:Twenty-one patients were fallen off after 6 weeks, and 129 patients completed the course of treatment. There was significantly decrease compared with HAMA,HAMD and PSQI scores in R+T group at the end of 2,4,6 weeks after treatment, the differences were statistically significant (P<0.05); the HAMA,HAMD and PSQI scores of R group were significantly decreased compared with before treatment at the end of 4,6 week, the differences were statistically significant (P<0.05); the HAMA, HAMD scores of T group were significantly decreased compared with before treatment , the differences were statistically significant (P<0.05).PSQI scores decreased significantly only at the end of 6 week, the differences were statistically significant (P<0.05). There were significant differences in HAMA,HAMD and PSQI scores of R+T group compared with group R and group T at the end of 2,4,6 week (P<0.05). Comparison of the TESS scores in the 3 group at the end of 4,6 weeks after treatment showed no significant differences (P＞0.05). CONCLUSION:Low dose risperidone combined with trazodone can significantly improve heroin addicts during detoxification of anxiety, depression and sleep quality. The effect of combined application is better than single drug use.

Key words: heroin addicts, trazodone, risperidone, anxiety, depression, insomnia

中图分类号:

蔡丹丹, 桂冬辉, 张建兵, 周文华. 小剂量利培酮联合曲唑酮应用于海洛因成瘾脱毒期的疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(1): 94-98.

CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua. Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 94-98.

参考文献

［1］施红辉，李荣文，蔡燕强.毒品成瘾矫治疗概论［M］.北京:科学出版社,2009:175-178．
［2］孙步青，叶遇高，秦领军.615例海洛因依赖者复吸原因调查与分析［J］.中国药物依赖性杂志，2001,10(3): 214-216.
［3］蔡丹丹，桂冬辉，张建兵，等.小剂量利培酮治疗海洛因依赖者心理渴求的临床疗效［J］.中国新药与临床杂志，2013,32(12):984-986．
［4］Freund-Levi Y，Jedenius E，Tysen-Backstrom AC，et al. Galantamine versus risperidone treatmentof neuropsychiatric symptoms in patients with probable dementia：an open randomized trial［J］.Am J Geriatr Psychiatry，2014,22(4):341-344．
［5］毛红京，刘义，徐莲莲. 曲唑酮与佐匹克隆治疗慢性睡眠障碍患者的临床疗效和安全性研究［J］.中国临床药理学与治疗杂志，2016,21(11):1288-1291．
［6］张作记.行为医学量表手册［M］.济宁:中华医学电子音像出版社，2005: 214-292.
［7］桂冬辉，蔡丹丹，黄燕燕，等.罗通定联合曲唑酮治疗稽延性戒断症状的临床研究［J］.中国临床药理学杂志，2014,4(30):309-311.
［8］那万秋，苏伟，李建华，等. 帕利哌酮和利培酮治疗精神分裂症的对照研究［J］.中国新药杂志，2011,20(8):708-710.
［9］Heler B，Samara MT，Huhn M，et al. Efficacy and safety of anti-depressants added to antipsychotics for schizophrenia： A systematic review and meta-analysis［J］．Am J Psychiatry，2016，173(9)：876-886.
［10］Cutler AJ.The role of insomnia in depression and anxiety:Its impact on functioning,treatment,and outcomes［J］.Clin Psychiatry,2016，77(8):1010-1015.
［11］钟慧军，彭亮，徐惠娟，等．多巴胺受体基因多态性与海洛因依赖的关联性研究［J］.中国现代医学杂志，2012,22(17):44-46．
［12］Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American academy of sleep medicine clinical practice guideline［J］ .Clin Sleep Med, 2017,13(2):307-349.
［13］蔡丹丹，桂冬辉，张建兵，等. 曲唑酮联合纳曲酮对海洛因依赖者防复吸的疗效［J］.中国新药与临床杂志，2014,33(11):827-830．
［14］陶用富，赵智慧，周豪．曲唑酮与丁丙诺啡治疗海洛因依赖者稽延性戒断症状的对照研究［J］. 中国药物滥用防治杂志，2010,16(5)：256-258.
［15］Wu Y, Yan S, Bao Y，et al. Cross-sectional study of the severity of self-reported depressive symptoms in heroin users whoparticipate in a methadone maintenance treatment program［J］. Shanghai Arch Psychiatry，2016，28(1)：35-41.
［16］涂亚婷，陈海波，陈美英. 碳酸锂合并小剂量利培酮治疗苯丙胺所致精神障碍的临床对照研究［J］. 现代诊断与治疗，2016，27（19）:3590-3591.
［17］赵彤，黄光彪，高晓磊，等. 不同剂量氨磺必利或利培酮对正常大鼠认知功能的影响［J］.临床精神医学杂志，2018,28(3):165-167.
［18］孙静.舍曲林联合小剂量利培酮治疗难治性强迫症效果分析［J］.中外医学研究，2016,14(11)：115-116．
［19］Cutler AJ. The role of insomnia in depression and anxiety: Its impact on functioning, treatment, and outcomes［J］. Clin Psychiatry，2016，77(8)：e1010.
［20］Yi XY, Ni SF, Ghadami MR, et al. Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials［J］. Sleep Med, 2018，5（45）：25-32.
［21］林壮国，宋珈莹，许佩娜，等.小剂量利培酮強化抗抑剂治疗双相抑郁发作的疗效观察［J］.现代诊断与治疗，2015,26(17):3885-3886.
［22］李娟，付艳梅. 小剂量抗精神病药联合心理疗法治疗躯体化障碍的疗效观察［J］.中国实用神经疾病杂志，2017,20(4):17-19.

[1]	张涛涛, 苏文秀, 田利民. 亚临床甲状腺功能减退症和抑郁的相关性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 954-960.
[2]	吴雄志, 王宣, 徐四七, 居霞, 王胜斌, 陈永权. 咪达唑仑口服溶液比右美托咪定喷鼻更有效缓解儿童术前焦虑[J]. 中国临床药理学与治疗学, 2023, 28(6): 666-670.
[3]	于泽芳, 范理菊, 尹晓玉, 高丽丽, 董占军. 新型速效抗抑郁药的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 595-600.
[4]	何滕, 许向阳, 徐祥清, 刘存明, 杨春. 氯胺酮治疗抑郁症的过去、现在及未来[J]. 中国临床药理学与治疗学, 2022, 27(10): 1125-1132.
[5]	王叶情, 王宇红, 刘检, 赵洪庆, 邹蔓姝. 胆囊收缩素与抑郁症的相关性研究进展[J]. 中国临床药理学与治疗学, 2021, 26(6): 672-679.
[6]	赵正卿, 李雁鹏, 向小霞, 庄建华, 赵忠新. 慢性失眠的发病机制与认知行为治疗[J]. 中国临床药理学与治疗学, 2021, 26(5): 482-486.
[7]	李雁鹏, 赵正卿, 王雯雯, 庄建华, 赵忠新. 慢性失眠临床诊断与药物治疗研究现状[J]. 中国临床药理学与治疗学, 2021, 26(5): 487-490.
[8]	陈颖, 袁勇贵. 中药单体、药对、复方、中成药治疗抑郁症研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 586-593.
[9]	金晶, 程虹. 线粒体能量代谢参与抑郁症发病的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1193-1199.
[10]	杨世涛, 祝一虹, 唐文新. 阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 937-942.
[11]	葛薇，盛文燕，许琦彬，李秋实，苏铃雅，吴双庆. 选择性5-羟色胺再摄取抑制剂类抗抑郁药舍曲林对产后抑郁患者眼表功能影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 440-446.
[12]	冯睿，张佳莉，赫明超，李钺，张岩. 中药及其活性成分防治抑郁症的药理靶点与临床应用[J]. 中国临床药理学与治疗学, 2020, 25(4): 467-474.
[13]	孙霄，杨素荣，李善群，王毅群. 快眼动睡眠调节机制及影响药物[J]. 中国临床药理学与治疗学, 2020, 25(2): 214-220.
[14]	桂冬辉, 蔡丹丹, 张建兵, 朱华强, 周文华. 曲唑酮联合认知行为治疗在社区戒毒模式管理中应用价值的初步研究[J]. 中国临床药理学与治疗学, 2020, 25(11): 1276-1282.
[15]	张嘉萱, 邓顺顺, 邱玛丽, 杨双双. 利培酮单药或联合用药治疗后甲状腺激素水平的变化[J]. 中国临床药理学与治疗学, 2020, 25(10): 1145-1150.